A5038943073- Mercury impact and mitigation studies
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Heavy metals in environment
- Lymphoma Diagnosis and Treatment
- Avian ecology and behavior
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Chronic Myeloid Leukemia Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Heavy Metal Exposure and Toxicity
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Plant and animal studies
- Animal Behavior and Reproduction
- Insect and Pesticide Research
- Hemophilia Treatment and Research
- Cutaneous lymphoproliferative disorders research
- Viral-associated cancers and disorders
- Receptor Mechanisms and Signaling
- Pharmacological Effects and Assays
- Brain Metastases and Treatment
- Endometrial and Cervical Cancer Treatments
- Geochemistry and Elemental Analysis
Istituto Oncologico Veneto
2021-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2024
Policlinico S.Orsola-Malpighi
2023
Ospedale Castelfranco Veneto
2016-2020
Ospedale San Giacomo Apostolo
2019
Università Cattolica del Sacro Cuore
2003
Primary pancreatic lymphoma (PPL) is a rare disease representing 0.1% of malignant lymphomas, which lacks well-defined diagnostic and therapeutic protocols.To describe PPL clinical, histological characteristics, together with therapy outcome, in relatively large series patients.The study includes 39 patients, aged ≥15 years, observed from January 2005 to December 2018, 8 Italian Institutions.The main symptoms were abdominal pain (58%) jaundice (47%). Lactate dehydrogenase serum levels...
Coagulation screening prior to surgery is performed routinely worldwide identify patients at risk of bleeding during the procedure. Evidence from medical and surgical literature suggests that activated partial thromboplastin time (aPTT) alone suitable for predicting individual it current practice in our hospital measure this parameter.
Rituximab plus bendamustine (BR), and rituximab, bendamustine, cytarabine (R-BAC) are well-known induction therapies in elderly patients with mantle cell lymphoma (MCL), according to clinical guidelines. However, a direct comparison between the two regimens has never been performed.In this multicentre retrospective study, we compared outcome of newly diagnosed MCL, treated BR or R-BAC. Primary endpoint was 2-year progression-free survival (PFS). Inclusion bias assessed using propensity score...
Chronic myeloid leukemia (CML) is characterized by the fusion protein BCR::ABL1, a constitutively active tyrosine kinase. The frontline treatment, represented kinase inhibitors (TKIs), has dramatically improved clinical outcomes of patients. However, TKI resistance through various mechanisms been reported. In particular, BCR::ABL11 T315I mutation associated with to first- and second-generation TKIs poor survival outcomes. For patients harboring this mutation, treatments third generation are...
Gefitinib, erlotinib, and afatinib represent the approved first-line options for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Because pivotal trials frequently lack external validity, real-world data may help to depict diagnostic-therapeutic pathway treatment outcome in clinical practice.MOST is a multicenter observational study promoted by Veneto Oncology Network, aiming at monitoring of patients with nonsquamous EGFR-mutant NSCLC. We reported terms...
Following high-dose chemotherapy/bone marrow transplantation, patients are routinely, prophylactically transfused with platelet concentrates (PC) if they have a count ≤10×109/L or higher in the presence of risk factors for bleeding. However, whether such transfusions necessary clinically stable no bleeding, therapeutic transfusion strategy could be sufficient and safe, is still debated.The GIMEMA Haemostasis Thrombosis Working Party sent questionnaire to Italian haematology departments...
<i>Objective:</i> In this phase I–II study we explored the potential of combination weekly gemcitabine (GEM) and 24-hour continuous infusion 5-fluorouracil (5-FU) in order to determine toxicity profile pancreatic cancer. The efficacy drug was studied as a secondary endpoint. <i>Methods:</i> Twenty-one patients with histologically or cytologically proven unresectable metastatic previously untreated adenocarcinoma were included study. Two dose levels GEM two 5-FU...
Therapy-related myeloid neoplasms (t-MNs), which develop after cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, account 7%–8% of acute leukemia (AML). Worse outcomes and consequently shortened survival are associated with t-MNs as compared de novo AML. MNs being reported increasing frequency in successfully treated promyelocytic (APL), particular, before the introduction all- trans retinoic acid (ATRA) plus arsenic trioxide (ATO). Considering high curability APL,...